Tag Archives: head_and_neck_cancer

No Survival Benefit with Erbitux in Pancreatic Cancer

April 12, 2007 – 5:39 am

BOSTON APR 10, 2007 (Reuters) - ImClone Systems Inc. said on Tuesday that a late-stage trial of Erbitux (cetuximab) failed to extend survival in patients with pancreatic cancer.
Erbitux is already approved to treat colorectal cancer and head and neck cancer.
The 700-patient trial compared Erbitux in combination with gemcitabine to gemcitabine alone in patients with pancreatic […]

By DotCancer.Com | Posted in Dotcancer | Also tagged , | Comments (0)

ImClone’s Erbitux flunks new cancer trial

April 11, 2007 – 7:45 am

BOSTON (Reuters) — ImClone Systems Inc. said Tuesday that a late-stage trial of its cancer drug Erbitux failed to extend survival in patients with pancreatic cancer, sending its shares down more than 7.5 percent.
Erbitux, which is already approved to treat colorectal cancer and head and neck cancer, and generated worldwide sales of $1.1 billion in […]

By DotCancer.Com | Posted in Dotcancer | Also tagged , , | Comments (0)